

10/764,235

In re/ Application of O'Mahony and Lambkin
Application No. 10/764,235

Atty. Docket No. P26479-B USA
June 28, 2006
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Canceled).
2. (Previously presented) A composition comprising a peptide having an amino acid sequence as set forth in SEQ ID NO: 24.
3. (Canceled).
4. (Previously presented) The composition of Claim 2, further comprising an active agent, wherein said peptide is complexed to said active agent.
5. (Canceled).
6. (Previously presented) The composition of Claim 2, further comprising an active particle, wherein said peptide is complexed to said active particle.
7. (Currently amended) A method for enhancing movement of an active agent across a lipid membrane, comprising a administering the composition of claim 4 to said membrane complex ~~selected from the group consisting of a MTLP active agent complex and a MTLP active particle complex~~, wherein the peptide MTLP enhances movement of the active agent across the lipid membrane.
8. (Currently amended) A method for enhancing movement of an active particle across a lipid membrane, comprising a administering the composition of claim 4 to said membrane ~~MTLP active particle complex~~, wherein the peptide MTLP enhances movement of the active particle across the lipid membrane.

9. ~~(Canceled) A method for identifying a derivative of a MTLP having enhanced ability to transport an active agent across a lipid membrane, wherein the derivative of the MTLP competes for transport of FMLP across a membrane selected from the group consisting of a cell membrane, an intracellular membrane, the apical and basal membranes of an epithelial cell layer.~~

10. ~~(Canceled) The membrane of claim 9, wherein the epithelial cell layer is a polarized epithelial cell layer.~~

11. (Currently amended) A method for treating a pathological disorder in an animal, comprising orally administering to the animal in need of such treatment the composition of claim 4 ~~a complex selected from the group consisting of a MTLP active agent complex and a MTLP active particle complex~~, wherein an amount of the active agent effective to treat the pathological disorder is moved across the gastrointestinal epithelium of the animal into the circulation.

12. (Previously presented) A composition according to Claim 4, wherein the active agent is a viral DNA particle.

13. (Currently amended) A composition according to Claim 12, wherein the DNA is ~~in the form of~~ complexed with a membrane translocating peptide (MTLP)-coated liposome.

14. (Currently amended) A pharmaceutical composition comprising ~~a peptide~~ the composition according to Claim 2 and a pharmaceutical carrier.

15. (Previously presented) A pharmaceutical composition according to Claim 14, adapted for oral administration.

16 to 18. (Canceled)

19. (Previously presented) A composition for use in membrane translocation, the composition consisting of an MTLP comprising an amino acid sequence of SEQ ID NO: 24.

20. (Previously presented) A composition of Claim 19, wherein said MTLP is complexed to a liposome.

21. (Previously presented) A pharmaceutical composition comprising a composition according to Claim 19 and a pharmaceutical carrier.

22. (Previously presented) A pharmaceutical composition according to Claim 20, adapted for oral administration.

23. to 30. (Canceled)